Clinical trials: Diabetic Patient
Type 2 Diabetes
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.
- Trial name
- NCT01103414
- Testing
- Mitoglitazone, Pioglitazone
- Where
- 24 sites in United States
- Volunteers
- 356 people
- Sponsor
- Metabolic Solutions Development Company
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH301 (NCT00782340)
- Testing
- Droxidopa
- Where
- 21 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- Chelsea Therapeutics
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is…
- Trial name
- NCT00430040
- Testing
- Carvedilol Controlled Release (CR), lisinopril
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University at Buffalo
Gastroparesis, Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03426345
- Testing
- Relamorelin
- Where
- 240 sites in United States, Argentina and 13 more
- Volunteers
- 311 people
- Sponsor
- Allergan
Neuropathic Pain
Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
- Trial name
- NCT01743976
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University
Diabetic Macular Edema
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor…
- Trial name
- ALTIMETER (NCT04597918)
- Testing
- Faricimab
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes
Diabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.
- Trial name
- DIRECT (NCT00252733)
- Testing
- candesartan cilexetil
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 5,238 people
- Sponsor
- AstraZeneca
Diabetes
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
The study aims to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease (CVD), chronic kidney disease (CKD)…
- Trial name
- NCT04903496
- Where
- China
- Volunteers
- 1,233,162 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema, Ischemic Maculopathy
Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Anti-vascular endothelial growth factor (VEGF) drugs are the mainstay of therapy for diabetic macular edema (DME), substantially improving visual acuity for many diabetics worldwide, and proving effective for treatment of both…
- Trial name
- IMPACT (NCT03246152)
- Testing
- Bevacizumab
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Cairo University
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients
- Trial name
- NCT01708902
- Testing
- linagliptin2.5mg/metformin1000mg, linagliptin 5mg, Metformin 500mg
- Where
- 56 sites in China, Malaysia and 2 more
- Volunteers
- 876 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Wound Infection
Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
This study will determine the tissue penetration of tedizolid (Sivextro, Merck \& Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound…
- Conditions
- Diabetes, Wound Infection, Healthy Volunteers
- Trial name
- NCT02620787
- Testing
- Tedizolid, Microdialysis Catheter Insertion
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Nonproliferative Diabetic Retinopathy
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
- Trial name
- PANORAMA (NCT02718326)
- Testing
- Intravitreal aflibercept injection [IAI]
- Where
- 89 sites in United States, Germany and 4 more
- Volunteers
- 402 people
- Sponsor
- Regeneron Pharmaceuticals
Age-related Macular Degeneration, Central Retinal Vein Occlusion
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates.
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01640171
- Testing
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Retina Vitreous Associates of Florida
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-South (NCT01217463)
- Testing
- Trafermin 0.01% spray
- Where
- 24 sites in Czechia, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Olympus Biotech Corporation
Diabetic Foot Ulcer
The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers
The purpose of this study is to determine whether the gentamicin-collagen sponge when combined with standard daily wound care and an oral antibiotic (levofloxacin) is safe and effective in treating moderately infected skin ulcers…
- Trial name
- NCT00659646
- Testing
- gentamicin-collagen sponge and levofloxacin, Levofloxacin only
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Innocoll
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.